Predicting relapse in favorable histology wilms tumor using gene expression analysis: A report from the renal tumor committee of the children's oncology group

Clinical Cancer Research

Volumn 15, Issue 5, 2009, Pages 1770-1778

  Huang, Chiang Ching ^a   Gadd, Samantha ^a   Breslow, Norman ^b   Cutcliffe, Colleen ^a   Sredni, Simone T ^a   Helenowski, Irene B ^a   Dome, Jeffrey S ^c   Grundy, Paul E ^d   Green, Daniel M ^e   Fritsch, Michael K ^f   Perlman, Elizabeth J ^a,g  

^a NORTHWESTERN UNIVERSITY   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

^d UNIVERSITY OF ALBERTA   (Canada)

^e ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^f UNIVERSITY OF WISCONSIN MADISON   (United States)

^g Box 17 ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD40 ANTIGEN; MAMMALIAN TARGET OF RAPAMYCIN; WNT PROTEIN;

APOPTOSIS; ARTICLE; CANCER LOCALIZATION; CANCER PATIENT; CANCER RELAPSE; CANCER STAGING; CHROMOSOME MAP; EPIGENETICS; GENE EXPRESSION; HISTOLOGY; HUMAN; MAJOR CLINICAL STUDY; NEPHROBLASTOMA; OVERALL SURVIVAL; PATIENT SELECTION; PREDICTION; PRIORITY JOURNAL; PROTEIN TARGETING; SENSITIVITY AND SPECIFICITY;

CHILD; FEASIBILITY STUDIES; GENE EXPRESSION PROFILING; HUMANS; KIDNEY NEOPLASMS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL; WILMS TUMOR;

EID: 63449130278     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-08-1030     Document Type: Article

References (49)

1. Green DM. The treatment of stages I-IV favorable histology Wilms tumor. J Clin Oncol 2004;22: 1366-72.
2. Breslow NE, Ou SS, Beckwith JB, et al. Doxorubicin for favorable histology, stage II-III Wilms tumor: results from the National WilmsTumor Studies. Cancer 2004; 101:1072-80.
3. Grundy RG, Hutton C, Middleton H, et al. Outcome of patients with stage III or inoperable WT treated on the second United Kingdom WT protocol (UKWT2);a United Kingdom Children's Cancer Study Group (UKCCSG) study. Pediatr Blood Cancer 2004;42: 311-9.
4. Grundy PE, Breslow NE, Li S, et al. Loss of heterozygosity for chromosomes 1p and 16q is an adverse prognostic factor in favorable-histology Wilms tumor: a report from the National Wilms Tumor Study Group. J Clin Oncol 2005;23:7312-21.
5. Huang CC, Cutcliffe C, Coffin C, Sorensen PH, Beck-with JB, Perlman EJ. Classification of malignant pediatric renal tumors by gene expression. Pediatr Blood Cancer 2006;46:728-38.
6. Zhang L, Miles MF, Aldape KD. A model of molecular interactions on short oligonucleotide microarrays. Nat Biotechnol 2003;21:818-21.
7. VapnikVN. Statistical learning theory. New York (NY): JohnWileyandSons;1998.
8. Simon R, Radmacher MD, Dobbin K, McShane LM. Pitfalls in the use of DNA microarray data for diagnostic and prognostic classification. J Natl Cancer Inst 2003;95:14-8.
9. Green DM, Breslow NE, Beckwith JB, et al. Treatment with nephrectomy only for small, stage I/favorable histology Wilms tumor: a report from the National Wilms Tumor Study Group.JClin Oncol 2001;19:3719-24.
10. Michiels S, Koscielny S, Hill C. Prediction of cancer outcome with microarrays: a multiple random validation strategy. Lancet 2005;365:488-92.
11. Storey JD. Adirect approach of false discovery rates. JR Stat Soc Ser B 2002;64:479-98.
12. Beckwith JB, Palmer NF. Histopathology and prognosis of Wilms tumors: results from the First National Wilms Tumor Study. Cancer 1978;41:1937-48.
13. Zirn B, Hartmann O, Samans B, et al. Expression profiling of Wilms tumors reveals new candidate genes for different clinical parameters. Int J Cancer 2006;118:1954-62.
14. Williams RD, Hing SN, Greer BT, et al. Prognostic classification of relapsing favorable histology Wilms tumor using cDNA microarray expression profiling and support vector machines. Genes Chromosomes Cancer2004;41:65-79.
15. Li W, Kessler P, Yeger H, et al. Agene expression signature for relapse of primary Wilms tumors. Cancer Res2005;65:2592-601.
16. Hanavadi S, Martin TA, Watkins G, Mansel RE, Jiang WG. Expression of interleukin 11 and its receptor and their prognostic value in human breast cancer. Ann Surg Oncol 2006;13:802-8.
17. Wright KO, Messing EM, Reeder JE. Increased expression of the acid sphingomyelinase-like protein ASML3a in bladder tumors. J Urol 2002;168: 2645-9.
18. KudoY, Ogawa I, Kitajima S, et al. Periostin promotes invasion and anchorage-independent growth in the metastatic process of head and neckcancer. Cancer Res 2006;66:6928-35.
19. Bao S, Ouyang G, Bai X, et al. Periostin potently promotes metastatic growth of colon cancer by augmentingcell survival via the Akt/PKB pathway. Cancer Cell 2004;5:329-39.
20. Kim CJ, Yoshioka N, Tambe Y, Kushima R, Okada Y, Inoue H. Periostin is down-regulated in high grade human bladder cancers and suppresses in vitro cell invasiveness and in vivo metastasis of cancer cells. Int J Cancer 2005;117:51 -8.
21. Natrajan R, Williams RD, Hing SN, et al. Array CGH profiling of favourable histology Wilms tumours reveals novel gains and losses associated with relapse. J Pathol 2006;210:49-58.
22. Kuefer R, Day KC, Kleer CG, et al. ADAM15 disintegrin is associated with aggressive prostate and breast cancer disease. Neoplasia 2006;8:319-29.
23. Bellone G, Carbone A, Tibaudi D, et al. Differential expression of transforming growth factors-βl, -β2 and β3 in human colon carcinoma. Eur J Cancer 2001;37:224-33.
24. Wilkinson S, Paterson HF, Marshall CJ. Cdc42-MRCK and Rho-ROCK signalling cooperate in myosin phosphorylation and cell invasion. Nat Cell Biol 2005;7:255-61.
25. Huang J, Perez-Burgos L, PlacekBJ, et al. Repression of p53 activity by Smyd2-mediated methylation. Nature2006;444:629-32.
26. Takino T, Nakada M, Miyamori H, et al.JSAP1/JIP3 cooperates with focal adhesion kinase to regulate c- Jun N-terminal kinase and cell migration. J Biol Chem 2005;280:37772-81.
27. Deng Y, Wu X. Peg3/Pw1 promotes p53-mediated apoptosis by inducing Bax translocation from cytosol to mitochondria. Proc Natl Acad Sci U S A 2000;97: 12050-5.
28. Dowdy SC, Gostout BS, Shridhar V, et al. Biallelic methylation and silencing of paternally expressed gene 3 (PEG3) in gynecologic cancer cell lines. Gynecol Oncol 2005;99:126-34.
29. Kim R. Recent advances in understanding the cell death path ways activated by anticancer therapy. Cancer2005;103:1551 -60.
30. Bonavida B, Huerta-Yepez S, GoodglickL, Mizutani Y, Miki T. Can we develop biomarkers that predict response of cancer patients to immunotherapy? Biomarkers2005;10Suppl1:S69-76.
31. Tirro E, Consoli ML, Massimino M, et al. Alterede- xpression of c-IAP1, survivin, and Smac contributes to chemotherapy resistance in thyroid cancer cells. Cancer Res2006;66:4263-72.
32. Pils D, HorakP, Gleiss A, et al. Five genes from chromosomal band 8p22 are significantly down-regulated in ovarian carcinoma: N33 and EFA6R have a potential impact on overall survival. Cancer 2005;104:2417-29.
33. Li Q, Jedlicka A, Ahuja N, et al. Concordant methylation of the ER and N33 genes in glioblastoma multiforme. Oncogene1998;16:3197-202.
34. Noda M, Oh J, Takahashi R, Kondo S, Kitayama H, Takahashi C. RECK: a novel suppressor of malignancy linking oncogenic signaling to extracellular matrix remodeling. Cancer Metastasis Rev 2003;22:167-75.
35. ChoC Y, Wang JH, Chang HC, Chang CK, Hung WC. Epigenetic inactivation of the metastasis suppressor RECK enhances invasion of human colon cancer cells. J Cell Physiol 2007;213:65-9.
36. Hay N, Sonenberg N. Upstream and downstream of mTOR. GenesDev2004;18: 1926-45.
37. Faivre S, Kroemer G, Raymond E. Current development of mTOR inhibitors as anticancer agents. Nat Rev Drug Discov 2006;5:671 -88.
38. Dallman C, Johnson PW, Packham G.Differential regulation of cell survival by CD40. Apoptosis 2003;8:45-53.
39. LuY, LemonW, Liu PY, et al. Agene expression signature predicts survival of patients with stage I non-small cell lung cancer. PLoS Med 2006;3:e467.
40. Reichling T, Goss KH, Carson DJ, et al. Transcriptional profiles of intestinal tumors in Apc(Min) mice are unique from those of embryonic intestine and identify novel gene targets dysregulated in human colorectal tumors. CancerRes2005;65:166-76.
41. Shimokawa T, Furukawa Y, Sakai M, et al. Involvement of the FGF18 genein colorectal carcinogenesis, as a novel downstream target of the β-catenin/T-cell factor complex. Cancer Res2003;63:6116-20.
42. Katoh M, Katoh M. Cross-talkofWNTand FGF signaling pathways at GSK3β to regulate β-catenin and SNA IL signaling cascades. Cancer Biol Ther 2006;5:1059-64.
43. Maiti S, Alam R, Amos CI, Huff V. Frequent associationofhβ- cateninandWT1mutationsinWilmstumors. Cancer Res 2000;60:6288-92.
44. Rivera MN, Kim WJ, Wells J, et al. An X chromosome gene, WTX, is commonly inactivated in Wilms tumor.Science2007;315:642-5.
45. Major MB, Camp ND, Berndt JD, et al.Wilms tumor suppressor WTX negatively regulatesWNT/β-catenin signaling. Science2007;316:1043-6.
46. Bentov I, LeRoith D, Werner H. The WT1 Wilms tumor suppressor gene: a novel target for insulin-like growth factor-I action. Endocrinology 2003;144:4276-9.
47. Natrajan R, Reis-Filho JS, Little SE, et al. Blastemal expression of type I in sulin-like growth factor receptor in Wilms tumors is driven by increased copy number and correlates with relapse. Cancer Res 2006;66:11148-55.
48. Granerus M, Johannisson A, Ekblom P, Engstrom W. Insulin-like growth factors I and II induce cell death in Wilmss tumour cells. Mol Pathol 2001;54:30-5.
49. Lu YJ, Hing S, Williams R, Pinkerton R, Shipley J, Pritchard-Jones K. Chromosome1q expression profiling and relapse in Wilms tumour. Lancet 2002;360:385-6.